

RESEARCH ARTICLE

# The Viral Polymerase Inhibitor 7-Deaza-2'-C-Methyladenosine Is a Potent Inhibitor of *In Vitro* Zika Virus Replication and Delays Disease Progression in a Robust Mouse Infection Model

Joanna Zmurko<sup>1</sup>, Rafael E. Marques<sup>2</sup>, Dominique Schols<sup>1</sup>, Erik Verbeken<sup>3</sup>, Suzanne J. F. Kaptein<sup>1‡</sup>, Johan Neyts<sup>1\*†</sup>

**1** Laboratory of Virology and Chemotherapy, KU Leuven - University of Leuven, Leuven, Belgium, **2** Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, **3** Department of Pathology, University of Leuven and Leuven University Hospitals, Leuven, Belgium

‡ These joint senior authors contributed equally to this work.

\* [Johan.Neyts@rega.kuleuven.be](mailto:Johan.Neyts@rega.kuleuven.be)



**OPEN ACCESS**

**Citation:** Zmurko J, Marques RE, Schols D, Verbeken E, Kaptein SJF, Neyts J (2016) The Viral Polymerase Inhibitor 7-Deaza-2'-C-Methyladenosine Is a Potent Inhibitor of *In Vitro* Zika Virus Replication and Delays Disease Progression in a Robust Mouse Infection Model. *PLoS Negl Trop Dis* 10(5): e0004695. doi:10.1371/journal.pntd.0004695

**Editor:** Ann M Powers, Centers for Disease Control and Prevention, UNITED STATES

**Received:** February 26, 2016

**Accepted:** April 15, 2016

**Published:** May 10, 2016

**Copyright:** © 2016 Zmurko et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the paper and its Supporting Information files.

**Funding:** JZ's work was supported by: EU FP7 [FP7/2007-2013] project EUVIRNA under grant agreement n° [264286] [http://cordis.europa.eu/result/rcn/176954\\_de.html](http://cordis.europa.eu/result/rcn/176954_de.html), a grant from the Belgian Interuniversity Attraction Poles (IAP) phase VII – P7/45 (BELVIR) and the Fondation Dormeur, Vaduz. Part of this research work was performed using the 'Caps-It' research infrastructure (project ZW13-02) that was financially supported by the Hercules Foundation and

## Abstract

Zika virus (ZIKV) is an emerging flavivirus typically causing a dengue-like febrile illness, but neurological complications, such as microcephaly in newborns, have potentially been linked to this viral infection. We established a panel of *in vitro* assays to allow the identification of ZIKV inhibitors and demonstrate that the viral polymerase inhibitor 7-deaza-2'-C-methyladenosine (7DMA) efficiently inhibits replication. Infection of AG129 (IFN- $\alpha/\beta$  and IFN- $\gamma$  receptor knock-out) mice with ZIKV resulted in acute neutrophilic encephalitis with viral antigens accumulating in neurons of the brain and spinal cord. Additionally, high levels of viral RNA were detected in the spleen, liver and kidney, and levels of IFN- $\gamma$  and IL-18 were systematically increased in serum of ZIKV-infected mice. Interestingly, the virus was also detected in testicles of infected mice. In line with its *in vitro* anti-ZIKV activity, 7DMA reduced viremia and delayed virus-induced morbidity and mortality in infected mice, which also validates this small animal model to assess the *in vivo* efficacy of novel ZIKV inhibitors. Since AG129 mice can generate an antibody response, and have been used in dengue vaccine studies, the model can also be used to assess the efficacy of ZIKV vaccines.

## Author Summary

A robust cell-based antiviral assay was developed that allows to screen for and validate novel inhibitors of Zika virus (ZIKV) replication. The viral polymerase inhibitor 7-deaza-2'-C-methyladenosine (7DMA) was identified as a potent ZIKV inhibitor. A mouse model for ZIKV infections, which was validated for antiviral studies, demonstrated that 7DMA markedly delays virus-induced disease in this model.

Rega Foundation, KU Leuven. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

## Introduction

Zika virus (ZIKV), a mosquito-borne flavivirus, was first isolated from a febrile Rhesus monkey in the Zika Forest in Uganda in 1947 [1]. During the last 5 decades sporadic ZIKV infections of humans were reported in Gabon, Nigeria, Senegal, Malaysia, Cambodia and Micronesia [2,3,4], leading to a benign febrile disease called Zika fever. The latter is characterized by headache, maculopapular rash, fever, arthralgia, malaise, retro-orbital pain and vomiting [5,6]. In 2007, an epidemic of fever and rash associated with ZIKV infection was reported in Micronesia. During this outbreak 185 cases of ZIKV infections were confirmed. The seroprevalence in the affected region was 73% [7]. During the more recent ZIKV outbreak in French Polynesia [FP] between October 2013 and February 2014 over 30,000 people sought medical care [8,9]. Since then, ZIKV has spread to new areas in the Pacific, including New Caledonia, the Cook Islands, and Chile's Easter Island [7,10]. As of 2015 ZIKV is causing an epidemic in Central and South America with an increasing number of cases reported particularly in Brazil, Colombia and El Salvador [11–14], demonstrating that this is a truly emerging human pathogen. Hundreds of cases of Guillain-Barré syndrome have been reported in the wake of ZIKV infections [15,16,17]. As a result of a marked increase in the number of cases of microcephaly among infants born to virus-infected women, Zika has been declared a public health emergency of national importance in Brazil [16,17,18]. In addition, an increasing number of travelers returning sick from endemic regions were diagnosed with ZIKV [19–24]. The *Aedes aegypti* mosquito, the primary vector for ZIKV transmission, is expanding in all (sub-)tropical regions of the world and was recently reported to be present in California, USA [25].

There is neither a vaccine nor a specific antiviral therapy for the prevention or treatment of infections by ZIKV. The increasing incidence of Zika fever stresses the need for both preventive and therapeutic measures. We here report on the establishment of (i) a panel of assays that allow to identify inhibitors of ZIKV replication as well as (ii) a robust animal model of ZIKV infection with brain involvement. The viral polymerase inhibitor 7-deaza-2'-C-methyladenosine (7DMA) was identified as an inhibitor of *in vitro* ZIKV replication and was shown to reduce viremia and to delay the time to disease progression in virus-infected mice.

## Materials and Methods

### Compounds

Ribavirin, 1-(β-D-ribofuranosyl)-1H-1,2,4-triazole-3-carboxamide (Virazole; RBV) was purchased from ICN Pharmaceuticals (Costa Mesa, CA, USA). 2'-C-methylcytidine (2'CMC) and 7-deaza-2'-C-methyl-D-adenosine (7DMA) were purchased from Carbosynth (Berkshire, UK). Favipiravir (6-fluoro-3-hydroxy-2-pyrazinecarboxamide; T-705) and its defluorinated analogue T-1105 (3-hydroxypyrazine-2-carboxamide) were obtained as custom synthesis products from abcr GmbH (Karlsruhe, Germany).

### Cells and viruses

ZIKV (strain MR766, passaged five times in the insect cell line C6/36) was obtained from the European Virus Archive (EVA; <http://www.european-virus-archive.com/viruses/zika-virus-strain-mr766>). Lyophilized virus was reconstituted in DMEM and virus stocks were generated on C6/36 mosquito cell cultures (ATCC CRL-1660) grown in Leibowitz medium supplemented with 10% fetal calf serum (FCS), 1% non-essential amino acids (NEAA) and 20 nM HEPES at 28°C, without CO<sub>2</sub>. At the time ZIKV caused a complete cytopathic effect (CPE) [d5-d7 post infection; pi] the supernatant was harvested and viral titers were determined by endpoint titration on Vero cells (African Green monkey kidney cells; ECACC), Vero E6 cells (Vero C1008;

ATCC CRL-1586) and BHK-J21 cells (baby hamster kidney cells; ATCC CCL-10). For end point titrations, cells were seeded in a 96-well plate at  $5 \times 10^3$  or  $10^4$  cells/well in 100  $\mu$ L assay medium and allowed to adhere overnight. The next day, 100  $\mu$ L of ZIKV was added to each well, after which the virus was serially diluted (1:2). Following 5 days of incubation, culture medium was discarded and replaced with (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; MTS) and the absorbance was measured at 498 nm following a 1.5h-incubation period. Subsequently, cultures were fixed with ethanol and stained with 1% Giemsa staining solution (solution of azure B/azure II-eosin/methylene blue 1:12:2 (w/w/w) in glycerol/methanol 5:24 (v/v); total dye content: 0.6% (w/w) Sigma-Aldrich). The different cell types as well as ZIKV tested negative for mycoplasma.

### CPE-reduction assay

Vero cells were grown in growth medium, consisting of MEM (Life Technologies) supplemented with 10% FCS, 2 mM L-glutamine and 0.075% sodium bicarbonate (Life Technologies). Antiviral assays were performed using the same medium except that 10% FCS was replaced with 2% FCS, referred to as 'assay medium'. Vero cells were seeded at a density of  $10^4$  cells/well in a 96-well plate in 100  $\mu$ L assay medium and allowed to adhere overnight. To each well 100  $\mu$ L of culture medium containing 50% cell culture infectious doses (i.e., CCID<sub>50</sub>) of ZIKV was added, after which 2-fold serial dilutions of the compounds were added. Following 5 days of incubation CPE was determined by means of the MTS readout method and by microscopic evaluation of fixed and stained cells. In parallel, cell cultures were incubated in the presence of compound and absence of virus to evaluate a potential cytotoxic effect. The 50% effective concentration (EC<sub>50</sub>), which is defined as the compound concentration that is required to inhibit virus-induced CPE by 50%, and 50% cytotoxic concentration (CC<sub>50</sub>), which is defined as the compound concentration that is required to inhibit the cell growth by 50%, was visually determined. The Z' factor was calculated by the following formula  $1 - [3 \times (SD_{CC} + SD_{VC}) / (OD_{CC} - OD_{VC})]$ ; VC, virus control; CC, cell control.

### Virus yield reduction assay

Vero cells were seeded at a density of  $5 \times 10^4$  cells/well in 96-well plates in growth medium and allowed to adhere overnight. Cells were washed 3 times with PBS and incubated with 100  $\mu$ L CCID<sub>50</sub> (MOI~0.2) of ZIKV in assay medium for 1 h at 37°C. Next, cells were washed 3 times with PBS and 2-fold serial dilutions of the compounds were added. Supernatant was harvested at day 4 pi and stored at -80°C until further use. The EC<sub>50</sub> value, which is defined as the compound concentration that is required to inhibit viral RNA replication by 50%, was determined using logarithmic interpolation.

### Viral kinetics and time-of-drug addition studies

Vero cells were seeded at a density of  $2 \times 10^5$  cells/well in 24-well plate in growth medium and allowed to adhere overnight. Cells were washed twice with PBS and incubated with ZIKV at an MOI~1 in assay medium for 30 min at 37°C. After the incubation, cells were washed twice with PBS, after which assay medium was added to the cells. Cells were harvested at 0, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24 hours pi and stored at -80°C until further use. For the time-of-drug addition studies, cells were seeded and infected as described above and 7DMA (178  $\mu$ M) or ribavirin (209  $\mu$ M) was added to the medium at different time points pi (see above). Cells were harvested at 24 hours pi and stored at -80°C until further use.

## Plaque reduction assay

Vero cells were cultured in growth medium. Cells were incubated with ZIKV for 1 h, washed and overlaid with a mixture of 2% (w/v) carboxymethylcellulose (Sigma Aldrich) and MEM supplemented with 2% FCS, 4 mM L-glutamine and 0.15% sodium bicarbonate. Two-fold serial dilutions of compounds were made in the overlay medium. Cells were fixed and stained using a 10% v/v formaldehyde solution and a 1% methylene blue solution, respectively. Infectious virus titer (PFU/mL) was determined using the following formula: number of plaques  $\times$  dilution factor  $\times$  (1/inoculation volume).

## Immunofluorescence assay

Vero cells were infected with ZIKV as described for the virus yield reduction assay. After removal of the virus, 2-fold serial dilution (starting at 89  $\mu$ M) of 7DMA was added to the cells. At 72 h pi, cells were subsequently fixed with 2% paraformaldehyde in PBS and washed with PBS supplemented with 2% BSA. Anti-Flavivirus Group Antigen Antibody clone D1-4G2-4-15 (Millipore) and goat anti-mouse Alexa Fluor 488 (Life Technologies) were used to detect ZIKV antigens in infected cells. Cell nuclei were stained using DAPI (4',6-diamidino-2-fenylindool; Life Technologies) and read out was performed using an ArrayScan XTI High Content Analysis Reader (Thermo Scientific). The EC<sub>50</sub> value, which is defined as the compound concentration that is required to inhibit viral antigen expression by 50%, was determined using logarithmic interpolation.

## RNA isolation and quantitative RT-PCR

RNA was isolated from 100–150  $\mu$ l supernatant using the NucleoSpin RNA virus kit (Filter Service, Germany) according to the manufacturer's protocol. RNA from infected cells was isolated using the RNeasy minikit (Qiagen, The Netherlands), according to the manufacturer's protocol, and eluted in 50  $\mu$ L RNase-free water. During RT-qPCR the ZIKV NS1 region (nucleotides 2472–2565) was amplified using primers 5'-TGA CTC CCC TCG TAG ACT G-3' and 3'-CTC TCC TTC CAC TGA TTT CCA C-5' and a Double-Quenched Probe 5'-6-FAM/AGA TCC CAC /ZEN/AAA TCC CCT CTT CCC/3'IABkFQ/ (Integrated DNA Technologies, IDT). Viral RNA was quantified using serial dilutions of a standard curve consisting of a synthesized gene block containing 145 bp of ZIKV NS1 (nucleotides 2456–2603): 5'-GGT ACA AGT ACC ATC CTG ACT CCC CTC GTA GAC TGG CAG CAG CCG TTA AGC AAG CTT GGG AAG AGG GGA TTT GTG GGA TCT CCT CTG TTT CTA GAA TGG AAA ACA TAA TGT GGA AAT CAG TGG AAG GAG AGC TCA ATG CAA TCC TAG-3' (Integrated DNA Technologies).

## A mouse model of Zika virus infection

All experiments were performed with approval of and under the guidelines of the Ethical Committee of the University of Leuven [P087-2014]. Virus stock was produced as described earlier and additionally concentrated by ultracentrifugation. Infectious virus titers (PFU/ml) were determined by performing plaque assays on Vero cells. 129/Sv mice deficient in both interferon (IFN)- $\alpha/\beta$  and IFN- $\gamma$  receptors (AG129 mice; male, 8–14 weeks of age) were inoculated intraperitoneally (ip; 200  $\mu$ L) with different inoculums ranging from  $1 \times 10^1$ – $1 \times 10^5$  PFU/mL of ZIKV. Mice were observed daily for body weight change and the development of virus-induced disease. In case of a body weight loss of >20% and/or severe illness, mice were euthanized with pentobarbital (Nembutal). Blood was collected by cardiac puncture and tissues (spleen, kidney, liver and brain) were collected in 2-mL tubes containing 2.8 mm zirconium oxide beads (Precellys/Bertin Technologies) after transcatheter perfusion using PBS. Subsequently, RLT lysis buffer (Qiagen) was added to the Precellys tubes and tissue homogenates were prepared using an automated homogenizer

(Precellys24; Bertin Technologies). Homogenates were cleared by centrifugation and total RNA was extracted from the supernatant using the RNeasy minikit (Qiagen), according to the manufacturer's protocol. For serum samples, the NucleoSpin RNA virus kit (Filter Service) was used to isolate viral RNA. Viral copy numbers were quantified by RT-qPCR, as described earlier.

## Histology

For histological examination, tissues (harvested at d13-15 pi) were subsequently fixed in 4% formaldehyde, embedded in paraffin, sectioned, and stained with hematoxylin-eosin, essentially as described before [26]. Anti-Flavivirus Group Antigen Antibody, clone D1-4G2-4-15 (Millipore) was used to detect ZIKV antigens in tissue samples.

## Detection of pro-inflammatory cytokines and chemokines

Induction of pro-inflammatory cytokines and chemokines was analyzed in 20  $\mu$ L serum using the mouse cytokine 20-plex antibody bead kit (ProcartaPlex Mouse Th1/Th2 & Chemokine Panel I [EPX200-26090-901]), which measures the expression of TNF- $\alpha$ , IFN- $\gamma$ , IL-6, IL-18, CCL2 (MCP-1), CCL3 (MIP-1 $\alpha$ ), CCL4 (MIP-1 $\beta$ ), CCL5 (RANTES), CCL7 (MCP-3), CCL11 (Eotaxin), CXCL1 (GRO- $\alpha$ ), CXCL2 (MIP-2), CXCL10 (IP-10), GM-CSF, IL-1 $\beta$ , IL12p70, IL-13, IL-2, IL-4, and IL-5. Measurements were performed using a Luminex 100 instrument (Luminex Corp., Austin, TX, USA) and were analyzed using a standard curve for each molecule (ProcartaPlex). Statistical analysis was performed using a one-way ANOVA.

## Evaluation of the activity of 7DMA in ZIKV-infected AG129 mice

AG129 mice (male, 8–14 weeks of age) were treated with either 50 mg/kg/day 7DMA resuspended in 0.5% or 0.2% sodium carboxymethylcellulose (CMC-Na; n = 9) or vehicle (0.5% or 0.2% CMC-Na; n = 9) once daily (QD) via oral gavage for 10 consecutive days. Since the bulk-forming agent CMC has dehydrating properties [27], mice that received the drug (or vehicle) formulated with 0.5% CMC received (on days 6–9) subcutaneous injections with 200  $\mu$ L of saline. One hour after the first treatment, mice were infected via the intraperitoneal route with 200  $\mu$ L of a  $1 \times 10^4$  PFU/ml stock of ZIKV. Blood was withdrawn from the tails at different days pi. Viral RNA was extracted from 20  $\mu$ L of serum using the RNA NucleoSpin RNA virus kit (Filter Service) followed by viral RNA quantification by means of RT-qPCR. Statistical analysis was performed using the Shapiro-Wilk normality test followed by the unpaired, two-tailed t-test in Graph Pad Prism6. Inter-group survival was compared using the Log-rank (Mantel-Cox) test. The *in vivo* efficacy of 7DMA was determined in two independent experimental animal studies. Evaluation of cytokine induction was performed using the ProcartaPlex Mouse Simplex IP-10 (CXCL10), TNF- $\alpha$ , IL-6 and IL-18 kits. In an additional animal study, AG129 mice (male, 8–14 weeks of age) were treated with 50 mg/kg/day 7DMA resuspended in 0.2% sodium carboxymethylcellulose (CMC-Na; n = 6) or vehicle (0.2% CMC-Na; n = 6) once daily (QD) via oral gavage for 5 successive days (starting 2 days prior to infection) and infected ip with 200  $\mu$ L of a  $1 \times 10^4$  PFU/ml stock of ZIKV. Animals were euthanized at day 5 pi and testicles were collected and stored until further use.

## Results

### Establishing *in vitro* antiviral assays and the identification of 7DMA as a selective inhibitor of *in vitro* ZIKV replication

End point titrations in different cell lines revealed that Vero cells are highly permissive to ZIKV, hence, these cells were selected to establish antiviral assays. Infection with  $100 \times \text{TCID}_{50}$

**Table 1. Antiviral and metabolic activity of a selection of compounds against ZIKV strain MR766.**

Compound	EC <sub>50</sub> (μM)				CC <sub>50</sub> (μM)	
	CPE	VY	PA	IFA	CPE	SI
Ribavirin	13 ± 0.2	12 ± 6.6	NA	NA	> 409	> 34
T-705	22 ± 15	24 ± 7.0	NA	NA	> 637	> 26
T-1105	86	35 ± 15	NA	NA	> 719	> 21
2'CMC	10 ± 0.4	3.9 ± 1.6	NA	NA	28 ± 10	7
7DMA	20 ± 15	9.6 ± 2.2	1.3	5.7 ± 2.2	> 357	> 37

Antiviral activity was determined in a CPE reduction assay (CPE), virus yield reduction assay (VY), plaque reduction assay (PA), and immunofluorescence assay (IFA); metabolic activity was determined in a CPE reduction assay. Data represent median values ± standard deviations (SD) from two independent experiments with 2 replicates for each experiment (n = 4), except for the result obtained in the PA. Selectivity index (SI) was calculated by dividing the CC<sub>50</sub> value by the EC<sub>50</sub> value (obtained in the VY assay). NA, not analyzed.


doi:10.1371/journal.pntd.0004695.t001

of ZIKV resulted in 100% cytopathic effect 5 days after infection (S1B Fig), as assessed by microscopic evaluation as well as by the MTS readout method. The Z' factor (a measure of statistical effect size to assess the quality of assays to be used for high-throughput screening purposes; [28]) of the CPE-reduction assay was 0.68 based on 64 samples (from 8 independent experiments) determined by the MTS readout method (S1C Fig). The assay is thus sufficiently stringent and reproducible for high throughput screening purposes (see also S2 Fig). The CPE-reduction assay was next employed to evaluate the potential anti-ZIKV activity of a selection of known (+)ssRNA virus inhibitors (i.e. 2'-C-methylcytidine, 7-deaza-2'-C-methyladenosine, ribavirin, T-705 and its analogue T-1105). All compounds resulted in a selective, dose-dependent inhibitory effect on ZIKV replication (Table 1). The antiviral effect of these compounds was confirmed in a virus yield reduction assay, a 1.7log<sub>10</sub> and 3.9log<sub>10</sub> reduction in viral RNA load at a concentration of 22 μM and ≥45 μM, respectively, was noted (Table 1 and Fig 1A). Since 7DMA resulted in the largest therapeutic window (SI > 37; Table 1), the antiviral activity of this compound was therefore next assessed in a plaque reduction assay and in an immunofluorescence assay to detect viral antigens. The inhibitory effect of the compound in both assays was in line with those of the CPE-reduction and virus yield reduction assay (Table 1, Fig 1A). At a concentration of 11 μM, 7DMA almost completely blocked viral antigen expression (Fig 1B, left panel).

7DMA is, as its 5'-triphosphate metabolite, an inhibitor of viral RNA-dependent RNA polymerases. Addition of the compound to infected cells could be delayed until ~10 hours pi without much loss of antiviral potency; when first added at a later time point, the antiviral activity was gradually lost. This is in line with the observation that onset of intracellular ZIKV RNA production was determined to occur at 10 to 12 hours pi (Fig 2). The reference compound ribavirin (a triazole nucleoside with multiple proposed modes of action; [29]), in contrast, already lost part of the antiviral activity when added at time points later than 4 hours pi (Fig 2).

### Establishing a ZIKV infection model in mice


Intraperitoneal inoculation of IFN-α/β and IFN-γ receptor knockout mice (AG129) with as low as 200 μL of a 1×10<sup>1</sup> PFU/ml stock of ZIKV resulted in virus-induced disease (see below) and mice had to be euthanized at a MDE (mean day of euthanasia) of 18.5 days pi (Fig 3A). Infection with higher inoculums (1×10<sup>2</sup>–1×10<sup>5</sup> PFU/ml; 200 μL) resulted in a faster progression of the disease (MDE of 14 days pi) with the first signs of disease appearing at day 10 pi. Surprisingly, inoculation of SCID mice with 200 μL of a 1×10<sup>4</sup> PFU/ml stock of ZIKV resulted



**Fig 1. Dose-dependent inhibition of ZIKV RNA replication by 7DMA.** (A) Vero cell cultures infected with ZIKV strain MR766 were treated with different concentrations of 7DMA. Viral RNA levels in the supernatant were quantified on day 4 pi by means of RT-qPCR and are expressed as percentage inhibition of untreated virus control (black bars). Mock-infected cells were treated with the same dilution series of 7DMA. Cell viability was determined by means of the MTS/PMS method and is expressed as percentage of cell growth of untreated control (white circles). Data represent mean values  $\pm$  standard deviations (SD) for three independent experiments. Log<sub>10</sub> reduction values in viral RNA load are depicted in italics at the top of each bar. (B) Antiviral activity of 7DMA against ZIKV as determined in an immunofluorescence assay. At a concentration of 11  $\mu$ M, 7DMA almost completely blocked viral antigen expression (left panel) compared to untreated, infected cells (right panel) and infected cells treated at a lower concentration (5.6 and 2.8  $\mu$ M; two panels in the middle).

doi:10.1371/journal.pntd.0004695.g001

in delayed disease; SCID mice had to be euthanized at day  $40.0 \pm 4.4$  pi, roughly 26 days later than AG129 mice (S3 Fig). Disease signs in AG129 mice included paralysis of the lower limbs, body weight loss, hunched back and conjunctivitis. High levels of viral RNA were detected in brain, spleen, liver and kidney from mice that were euthanized at day 13–15 pi (Fig 3B). Histopathological analysis on tissues collected at day 13–15 pi revealed the accumulation of viral




**Fig 2. Viral replication kinetics of ZIKV and time-of-drug-addition studies.** In viral kinetics studies, Vero cells were infected with ZIKV at an MOI=1.0 and harvested at the indicated time points pi. Data are expressed as percentage viral replication compared to viral RNA replication in infected cells at 24 hours pi (white circles). In time-of-drug-addition studies, ZIKV-infected cells were treated with 7DMA (178  $\mu$ M; black bars) or ribavirin (205  $\mu$ M; grey bars) at different time points pi. Cells were harvested at 24 hours pi and viral RNA was extracted and quantified by RT-qPCR. Data are expressed as percentage inhibition of viral replication compared to viral RNA replication in untreated, infected cells at 24 hours pi.

doi:10.1371/journal.pntd.0004695.g002

antigens in neurons of both the brain (Fig 4A) and the spinal cord (Fig 4D) as well as in hepatocytes (Fig 4E). Acute neutrophilic encephalitis (Fig 4C) was observed at the time of onset of virus-induced morbidity. It was next assessed whether infection with ZIKV resulted in the induction of a panel of 20 cytokines and chemokines at different time points pi (day 2, 3, 4 and 8; Figs 3C and 3D and S4A–S4G). In particular, levels of IFN- $\gamma$  and IL-18 were increased systematically and significantly during the course of infection (Fig 3C and 3D), whereas levels of IL-6, CCL2, CCL5, CCL7, CXCL1, CXCL10 and TNF- $\alpha$  first increased, reaching a peak level at day 3 pi (CCL2, CXCL1, TNF- $\alpha$ ; S4A–S4C Fig) or day 4 pi (IL-6, CCL7, CXCL10; S4D–S4F Fig) pi and then gradually declined. Levels of CCL5 subsequently increased at day 2 pi, dropped at day 3 pi, and gradually increased again at day 4 and 8 pi (S4G Fig).

### 7-deaza-2'-C-methyladenosine delays ZIKV-induced disease in AG129 mice

AG129 mice were infected with 200  $\mu$ L of a  $1 \times 10^4$  PFU/ml stock of ZIKV and were treated once daily with 50 mg/kg/day of 7DMA or vehicle *via* oral gavage (Fig 5) [data from the two independent experiments were not pooled since different amounts of CMC (respectively 0.5% and 0.2%) were used for formulation]. Vehicle-treated mice had to be euthanized two weeks after infection [MDE of 14.0 and 16.0 days, respectively]. 7DMA was well tolerated [no marked changes in body weight mass, fur, consistency of the stool or behavior during the treatment period] and markedly delayed virus-induced disease progression [MDE of 23.0 in the first study ( $p = 0.003$  as compared to the control) and 24.0 in the second study ( $p = 0.04$  as compared to the control)] (Fig 5A). 7DMA also reduced the viral RNA load in the serum of infected mice by  $0.5 \log_{10}$ ,  $0.8 \log_{10}$ ,  $0.9 \log_{10}$ ,  $0.7 \log_{10}$  and  $1.3 \log_{10}$ , respectively, at day 3, 5, 6, 7 and 8 pi (Fig 5B). Interestingly, at day 5 pi high levels of viral RNA ( $6.4 \log_{10}$ ) were found in the testicles of vehicle-treated mice (Fig 5C). At day 8 pi (shortly before the onset of disease in the vehicle




**Fig 3. Establishment and characterization of an animal model for ZIKV infection.** Male (8–14 weeks of age) 129/Sv mice deficient in both IFN-alpha/beta (IFN- $\alpha/\beta$ ) and IFN-gamma (IFN- $\gamma$ ) receptors (AG129) were inoculated intraperitoneally with 200  $\mu$ L of different inoculums (ranging from  $1 \times 10^1$ – $1 \times 10^5$  PFU/ml) of ZIKV. Mice were observed daily for body weight loss and the development of virus-induced disease. (A) Median day of euthanasia (MDE) is as follows: day 13.5, 15.0, 14.0, 14.5 and 18.5 pi for mice inoculated with  $1 \times 10^5$  (n = 6),  $1 \times 10^4$  (n = 6),  $1 \times 10^3$  (n = 5),  $1 \times 10^2$  (n = 2) and  $1 \times 10^1$  (n = 4) PFU/mL, respectively. (B) Viral RNA load in brain (n = 7), spleen (n = 5), kidney (n = 5) and liver (n = 6) from ZIKV-infected mice as determined by RT-qPCR. Levels of IFN- $\gamma$  (C) and IL-18 (D) were significantly increased throughout the course of infection in sera of AG129 mice (grey boxes) compared to those in sera of uninfected AG129 mice (white boxes). Statistical analysis was performed using the unpaired, two-tailed t-test. \*, p<0.05.

doi:10.1371/journal.pntd.0004695.g003

controls), levels of IFN- $\gamma$  in the serum were significantly higher in vehicle than in drug-treated mice (Fig 5D).

## Discussion


The rapid geographical spread of ZIKV, particularly in Central and South America poses a serious public health concern given that infection with this virus is less benign than initially thought. Hundreds of patients have been reported with Guillain-Barré syndrome [16,17]. Most importantly, in Brazil a dramatic upsurge in the number of cases of microcephaly has been



**Fig 4. Presence of ZIKV antigens in the brain (A), spinal cord (D) and liver (E) of ZIKV-infected AG129 mice, whereas ZIKV antigens were absent in tissues of uninfected mice (brain, B), as shown by histopathological analysis.** Infiltration of neutrophils is shown in the brain of ZIKV-infected mice (as detected by hematoxylin-eosin staining; C), but not in the brain of uninfected mice (F).

doi:10.1371/journal.pntd.0004695.g004

noted in children born to mothers infected with ZIKV. The annual rate of microcephaly in Brazil has increased from 5.7 per 100 000 live births in 2014 to 99.7 per 100 000 in 2015 [16,17,18]. There is, hence, an urgent need to develop preventive and counteractive measures against this truly neglected flavivirus member. We here report on the establishment of (i) *in vitro* assays that will allow to identify novel inhibitors of ZIKV replication and (ii) a ZIKV infection model in mice in which the potential efficacy of such inhibitors can be assessed. ZIKV was found to replicate efficiently in Vero cells and to produce full CPE within a couple of days. The Z' factor that was calculated for a colorimetric (MTS method) CPE-based screen indicated that this is a robust assay that is amenable for high-throughput screening purposes. A plaque reduction, an infectious virus yield and a viral RNA yield reduction assay as well as an immunofluorescent antigen detection assay were established that will allow to validate the *in vitro* activity of hits identified in CPE-based screenings. Productive infection of human dermal fibroblasts, epidermal keratinocytes and immature dendritic cells with the ZIKV has recently been reported [30]. However, Vero cells may be ideally suited for high throughput screening purposes, making these cells most useful to confirm the antiviral activity of interesting inhibitors of viral replication. We employed the assays that we established to assess the potential anti-ZIKV activity of a number of molecules with reported antiviral activity against other ssRNA viruses. In particular, the nucleoside analogue 7DMA was identified to inhibit ZIKV replication with a potency that was more or less comparable between the different *in vitro* assays. 7DMA was originally developed by Merck Research Laboratories as an inhibitor of hepatitis C virus replication [31], but was also shown to inhibit the replication of multiple flaviviruses, [i.e. dengue virus, yellow fever virus as well as West Nile and tick-borne encephalitis virus] with EC<sub>50</sub> values ranging between 5 and 15 μM, which is thus comparable to the EC<sub>50</sub> values for inhibition of *in vitro* ZIKV replication [31,32,33]. In line with its presumed mechanism of action, i.e. inhibition as its 5'-triphosphate of the viral RNA-dependent RNA polymerase, time-of-drug-addition experiments



**Fig 5. In vivo efficacy of 7DMA against ZIKV.** AG129 mice (male, 8–14 weeks of age; n = 9) were treated with 50 mg/kg/day 7DMA sodium carboxymethylcellulose (CMC-Na) via oral gavage or with vehicle [0.5% or 0.2% CMC-Na; n = 9] for 10 days. Mice were infected intraperitoneally with 200  $\mu$ L of a  $1 \times 10^4$  PFU/mL stock of ZIKV 1 hour after the first treatment on day 0. (A) Percentage survival between ZIKV-infected mice treated with vehicle (● and ■) or 7DMA (○ and □) was compared using the Log-rank (Mantel-Cox) test. Data represent results from 2 independently performed studies. (B) Viral RNA load in serum on day 1, 2, 3, 5, 6, 7 and 8 pi of ZIKV-infected mice treated with vehicle (white boxes) or 7DMA (grey boxes), as determined by RT-qPCR. Statistical analysis was performed using the unpaired, two-tailed t-test. Data are representative of 2 independent experiments. (C) Viral RNA load in testes of vehicle-treated, ZIKV-infected AG129 mice at day 5 pi, as determined by RT-qPCR. (D) Expression at different time points pi of IFN- $\gamma$  in sera of ZIKV-infected mice treated with vehicle (white boxes) or 7DMA (grey boxes), as determined using the ProcartaPlex Mouse IFN- $\gamma$ , IL-18, IL-6, IP-10, TNF- $\alpha$  Simplex kit (e-Bioscience). Data represent results from 2 independent experiments.

doi:10.1371/journal.pntd.0004695.g005

revealed that the compound acts at a time point that coincides with the onset of intracellular viral RNA replication.

To assess the *in vivo* efficacy of ZIKV inhibitors, we established a model of ZIKV infection in mice. AG129 mice proved highly susceptible to ZIKV infections; even an inoculum of  $\sim 10$  PFU/ml resulted in virus induced-morbidity and mortality. Although ZIKV-infected SCID mice (deficient in both T and B lymphocytes) developed severe disease requiring euthanasia (paralysis of the lower limbs, body weight loss, hunched back), these mice were more resistant to ZIKV infection than AG129 mice. SCID mice succumbed to infection roughly 26 days later than AG129 mice when inoculated with the same viral inoculum. Thus, ZIKV infections in mice are mostly controlled by the interferon response rather than by lymphocytes, indicating that the innate immune response to ZIKV is critical. AG129 mice have been shown to be highly susceptible to infection with other flaviviruses; in particular allowing the development of

dengue virus infection models in mice [32,34,35]. At the time of virus-induced morbidity and mortality, ZIKV was detected in multiple organs such as kidney, liver and spleen, but also in the brain and spinal cord. The latter is in line with the observation that infected mice developed acute neutrophilic encephalitis with movement impairment and paralysis of the limbs. Brain involvement in ZIKV-infected mice may be relevant for brain-related pathologies in some ZIKV-infected humans [16,17]. Interestingly, the virus was also detected at high levels in the testicles of infected mice. A few cases of sexual transmission of the ZIKV in humans have been reported [36,37]; the observation that the virus replicates in the testicles in mice may suggest that the virus can also replicate in human testicle tissue thus explaining sexual transmission.

Pro-inflammatory cytokines (IFN- $\gamma$ , IL-18, IL-6, TNF- $\alpha$ ) and chemokines (CCL2, CCL5, CCL7, CXCL1, CXCL10) were found to be increased in sera of ZIKV-infected mice, indicating that infection causes systemic inflammation. In particular IFN- $\gamma$  and IL-18 were continuously increased during the course of infection; both cytokines could therefore potentially function as predictive markers of disease progression and disease severity in this mouse model. Whether these cytokines are also upregulated during the acute phase of the infection in humans remains to be studied. Of note, the fact that ZIKV infection leads to the production of IL-18 suggests that the inflammasome is activated during the course of infection. Surprisingly, we could detect increased levels of IL-18, but not of IL-1 $\beta$ , which is also produced upon activation of the inflammasome [38]. To our knowledge, the observation that the inflammasome could be implicated in ZIKV infection is unprecedented.

Recently, a small study was reported involving 6 ZIKV-infected patients in which during the acute phase 11 cytokines/chemokines were found to be significantly increased, of which 7 were also increased during recovery [39]. Despite the fact that immunocompromised AG129 mice have an altered cytokine metabolism and were infected with the prototype ZIKV MR766 strain belonging to a different lineage than the one infecting the Latin American patients (African versus Asian, respectively), similarities in cytokine expression were noted between both studies. IL-6, CCL5 and CXCL10 were significantly increased in ZIKV-infected patients as well as in the infected mice. In the ZIKV-infected patients IFN- $\gamma$  levels, which were markedly increased in ZIKV-infected mice, were also increased during both the acute and the convalescent phase of the infection, albeit non-significantly. Likewise, TNF- $\alpha$  levels, which were increased early in infection in mice, were (non-significantly) increased during the acute phase of infection in the patients. More studies are necessary to assess whether the cytokine profile in these 6 patients is representative for larger groups.

Treatment of ZIKV-infected mice with 7DMA significantly reduced viremia (between day 3 and 8 post infection) and delayed virus-induced morbidity and mortality. The compound was very well tolerated in mice, which is in line with earlier reports [31]. The reduction in viremia and, hence, the delay of virus-induced disease was relatively modest, which is not surprising given the relatively weak *in vitro* activity of the compound as compared to, for example, the EC<sub>50</sub> values (sub  $\mu$ M or even nM range) of most HCV inhibitors. Most importantly, the use of this compound allowed to validate the ZIKV mouse model to assess the efficacy of ZIKV inhibitors. Whether 7DMA (or related analogues) may have future in the control of ZIKV infections remains to be explored. AG129 mice have been used as well in the development of DENV vaccines, the DENV AG120 mouse models offer multiple disease parameters to evaluate protection by candidate vaccines [40]. Hence, the ZIKV mouse model presented here may also serve to study the efficacy of vaccine strategies against the ZIKV.

In conclusion, we here report on a panel of *in vitro* cellular assays that will allow to run large-scale antiviral screening campaigns against ZIKV and to validate the antiviral activity of hit compounds. A number of molecules, including the viral polymerase inhibitor 7DMA, were found to inhibit the *in vitro* replication of ZIKV. Hence, 7DMA can be used as a reference

compound/comparator in future studies. Moreover, a robust ZIKV mouse infection model was established; 7DMA delayed virus-induced mortality and, hence, validates this model for antiviral studies. Moreover, the model may be useful to study the efficacy of vaccination strategies against the ZIKV.

## Supporting Information

**S1 Fig. CPE reduction assay.** Vero cells infected with ZIKV MR766 causes full CPE (B) at day 5 pi; uninfected cells (A). Z' factor (0.68) was calculated for 64 samples (in 8 independent experiments; C) determined by the MTS readout method using the formula:  $1 - [3 \times (SD_{CC} + SD_{VC}) / (OD_{CC} - OD_{VC})]$ ; VC, virus control; CC, cell control. (PDF)

**S2 Fig. CPE reduction assay performed on a 384-well plate format.** Vero E6 cells were infected with ZIKV MR766 in the presence of (3-fold serial dilutions of) a panel of compounds (2'-C-methyladenosine [2'CMA], 2'-C-methylguanosine [2'CMG], 2'-C-methylcytidine [2'CMC], 7-deaza-2'-C-methyladenosine [7DMA], ribavirin, favipiravir [T-705] and T-1105). Cells were fixed and stained using a 1% methylene blue solution at day 7 pi. (TIF)

**S3 Fig. Kaplan-Meier curve showing median day of euthanasia (MDE) of ZIKV-infected SCID mice.** Male (8–9 weeks of age) SCID mice deficient in both T and B lymphocytes were inoculated intraperitoneally with 200  $\mu$ L of  $1 \times 10^4$  PFU/ml of ZIKV MR766. Mice were observed daily for body weight loss and the development of virus-induced disease. In case of a body weight loss of >20% and/or severe illness, mice were euthanized using pentobarbital (Nembutal). (EPS)

**S4 Fig. Box-and-whiskers plots showing increased levels of a panel of cytokines and chemokines that were increased in sera of ZIKV-infected mice (grey boxes) at different days pi compared to those in sera of non-infected mice (white boxes): (A) CCL2, (B) CXCL1, (C) TNF- $\alpha$ , (D) IL-6, (E) CXCL10, (F) CCL5 and (G) CCL7.** Induction of cytokines and chemokines was detected in 20  $\mu$ L of serum using the ProcartaPlex Multiplex Immunoassay Panel with Mouse Th1/Th2 & Chemokine Panel 20-Plex (e-Bioscience). Statistical analysis was performed using a one-way ANOVA. \*,  $p < 0.05$ . (PDF)

## Acknowledgments

We thank Els Vanstreels, Carolien De Keyzer, Natasha Danda, Sandra Claes, Mareike Grabner and Ruben Pholien for excellent technical assistance.

## Author Contributions

Conceived and designed the experiments: JZ REM SJFK JN. Performed the experiments: JZ SJFK REM. Analyzed the data: JZ REM SJFK EV. Contributed reagents/materials/analysis tools: EV DS JN. Wrote the paper: JZ SJFK REM JN.

## References

1. Dick GW, Kitchen SF, Haddock AJ. Zika virus. I. Isolations and serological specificity. *Trans R Soc Trop Med Hyg.* 1952; 46(5):509–20. PMID: [12995440](https://pubmed.ncbi.nlm.nih.gov/12995440/)

2. Grard G, Caron M, Mombo IM, Nkoghe D, Mboui Ondo S, Jiolle D, et al. Zika Virus in Gabon (Central Africa) - 2007: a new threat from *Aedes albopictus*? *PLoS Negl Trop Dis*. 2014; 8(2):e2681. doi: [10.1371/journal.pntd.0002681](https://doi.org/10.1371/journal.pntd.0002681) PMID: [24516683](https://pubmed.ncbi.nlm.nih.gov/24516683/)
3. Haddow AD, Schuh AJ, Yasuda CY, Kasper MR, Heang V, Huy R, et al. Genetic characterization of Zika virus strains: geographic expansion of the Asian lineage. *PLoS Negl Trop Dis*. 2012; 6(2):e1477. doi: [10.1371/journal.pntd.0001477](https://doi.org/10.1371/journal.pntd.0001477) PMID: [22389730](https://pubmed.ncbi.nlm.nih.gov/22389730/)
4. Diallo D, Sall AA, Diagne CT, Faye O, Faye O, Ba Y, et al. Zika Virus Emergence in Mosquitoes in Southeastern Senegal, 2011. *PLoS One*. 2014; 9(10):e109442. doi: [10.1371/journal.pone.0109442](https://doi.org/10.1371/journal.pone.0109442) PMID: [25310102](https://pubmed.ncbi.nlm.nih.gov/25310102/)
5. European Centre for Disease Prevention and Control. Rapid risk assessment: Zika virus infection outbreak, French Polynesia. 14 February 2014. Stockholm: ECDC; 2014.
6. Centers for Disease Control and Prevention. Zika Virus. Symptoms & Treatment [cited 2015 Dec 17]. <http://www.cdc.gov/zika/symptoms/index.html>
7. Iosifidis S, Mallet HP, Leparc Goffart I, Gauthier V, Cardoso T, Herida M. Current Zika virus epidemiology and recent epidemics. *Med Mal Infect*. 2014; 44(7):302–7. doi: [10.1016/j.medmal.2014.04.008](https://doi.org/10.1016/j.medmal.2014.04.008) PMID: [25001879](https://pubmed.ncbi.nlm.nih.gov/25001879/)
8. Musso D, Nilles EJ, Cao-Lormeau VM. Rapid spread of emerging Zika virus in the Pacific area. *Clin Microbiol Infect*. 2014; 20(10):O595–6. doi: [10.1111/1469-0691.12707](https://doi.org/10.1111/1469-0691.12707) PMID: [24909208](https://pubmed.ncbi.nlm.nih.gov/24909208/)
9. Cao-Lormeau VM, Roche C, Teissier A, Robin E, Berry AL, Mallet HP, et al. Zika virus, French polynesia, South pacific, 2013. *Emerg Infect Dis*. 2014; 20(6):1085–6. doi: [10.3201/eid2006.140138](https://doi.org/10.3201/eid2006.140138) PMID: [24856001](https://pubmed.ncbi.nlm.nih.gov/24856001/)
10. Rodriguez-Morales AJ. Zika: the new arbovirus threat for Latin America. *J Infect Dev Ctries*. 2015; 9(6):684–5. doi: [10.3855/jidc.7230](https://doi.org/10.3855/jidc.7230) PMID: [26142684](https://pubmed.ncbi.nlm.nih.gov/26142684/)
11. Fauci AS, Morens DM. Zika Virus in the Americas—Yet Another Arbovirus Threat. *N Engl J Med*. 2016 Jan 13. [Epub ahead of print]
12. Campos GS, Bandeira AC, Sardi SI. Zika Virus Outbreak, Bahia, Brazil. *Emerg Infect Dis*. 2015; 21(10):1885–6. doi: [10.3201/eid2110.150847](https://doi.org/10.3201/eid2110.150847) PMID: [26401719](https://pubmed.ncbi.nlm.nih.gov/26401719/)
13. Musso D. Zika Virus Transmission from French Polynesia to Brazil. *Emerg Infect Dis*. 2015; 21(10):1887.
14. ProMEDmail. PRO/EDR> Zika virus—Americas (04). ProMed. 2015 Dec 11. <http://www.promedmail.org>. Archive no. 20151211.3855107.
15. Oehler E, Watrin L, Larre P, Leparc-Goffart I, Lastère S, Valour F, et al. Zika virus infection complicated by Guillain-Barré syndrome—case report, French Polynesia, December 2013. *Euro Surveill*. 2014; 19(9):pii = 20720.
16. European Centre for Disease Prevention and Control. Rapid risk assessment: Zika virus epidemic in the Americas: potential association with microcephaly and Guillain-Barré syndrome— 10 December 2015. Stockholm: ECDC; 2015.
17. Dyer O. Zika virus spreads across Americas as concerns mount over birth defects. *BMJ*. 2015 Dec 23; 351:h6983. doi: [10.1136/bmj.h6983](https://doi.org/10.1136/bmj.h6983) PMID: [26698165](https://pubmed.ncbi.nlm.nih.gov/26698165/)
18. Pan American Health Organization / World Health Organization. Neurological syndrome, congenital malformations, and Zika virus infection. Implications for public health in the Americas—Epidemiological Alert. 2015 Dec 01 [cited 2015 Dec 17]. [http://www.paho.org/hq/index.php?option=com\\_docman&task=doc\\_view&Itemid=270&gid=32405&lang=en](http://www.paho.org/hq/index.php?option=com_docman&task=doc_view&Itemid=270&gid=32405&lang=en)
19. Kutsuna S, Kato Y, Takasaki T, Moi M, Kotaki A, Uemura H, et al. Two cases of Zika fever imported from French Polynesia to Japan, December 2013 to January 2014. *Euro Surveill*. 2014; 19(4):1–4.
20. Zammarchi L, Stella G, Mantella A, Bartolozzi D, Tappe D, Günther S, et al. Zika virus infections imported to Italy: clinical, immunological and virological findings, and public health implications. *J Clin Virol*. 2015; 63:32–5. doi: [10.1016/j.jcv.2014.12.005](https://doi.org/10.1016/j.jcv.2014.12.005) PMID: [25600600](https://pubmed.ncbi.nlm.nih.gov/25600600/)
21. Wæhre T, Maagard A, Tappe D, Cadar D, Schmidt-Chanasit J. Zika virus infection after travel to Tahiti, December 2013. *Emerg Infect Dis*. 2014; 20(8):1412–4. doi: [10.3201/eid2008.140302](https://doi.org/10.3201/eid2008.140302) PMID: [25062427](https://pubmed.ncbi.nlm.nih.gov/25062427/)
22. Zammarchi L, Tappe D, Fortuna C, Remoli ME, Günther S, Venturi G, et al. Zika virus infection in a traveller returning to Europe from Brazil, March 2015. *Euro Surveill*. 2015; 20(23):pii = 21153. PMID: [26084316](https://pubmed.ncbi.nlm.nih.gov/26084316/)
23. Goorhuis A. Zika virus—Netherlands ex Suriname. ProMed. 2015 Dec 13. <http://www.promedmail.org>, archive no. 20151213.3858300.
24. McCarthy M. First US case of Zika virus infection is identified in Texas. *BMJ*. 2016; 352:i212. doi: [10.1136/bmj.i212](https://doi.org/10.1136/bmj.i212) PMID: [26762624](https://pubmed.ncbi.nlm.nih.gov/26762624/)

25. ProMEDmail. PRO/EDR> Invasive mosquito—USA (13): (CA). ProMed. 2015 Nov 13. <http://www.promedmail.org>. Archive no. 20151113.3789859.
26. Leyssen P, Croes R, Rau P, Heiland S, Verbeken E, Sciote R, et al. Acute encephalitis, a poliomyelitis-like syndrome and neurological sequelae in a hamster model for flavivirus infections. *Brain Pathol*. 2003; 13(3):279–90. PMID: [12946018](#)
27. Bischoff K, Mukai M. Toxicity of over-the-counter drugs. In: Gupta RC, editor. *Veterinary Toxicology: Basic and clinical principles*, 2nd ed. Cambridge (MA): Academic Press, 2012:443–68.
28. Iversen PW, Eastwood BJ, Sittampalam GS, Cox KL. A comparison of assay performance measures in screening assays: signal window, Z' factor, and assay variability ratio. *J Biomol Screen*. 2006; 11(3):247–52. PMID: [16490779](#)
29. Paeshuyse J, Dallmeier K, Neyts J. Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. *Curr Opin Virol*. 2011; 1(6):590–8. doi: [10.1016/j.coviro.2011.10.030](#) PMID: [22440916](#)
30. Hamel R, Dejarnac O, Wichit S, Ekcharyawat P, Neyret A, Luplertlop N, et al. Biology of Zika Virus Infection in Human Skin Cells. *J Virol*. 2015; 89(17): 8880–96. doi: [10.1128/JVI.00354-15](#) PMID: [26085147](#)
31. Olsen DB, Eldrup AB, Bartholomew L, Bhat B, Bosserman MR, Ceccacci A, et al. A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties. *Antimicrob Agents Chemother*. 2004; 48(10):3944–53. PMID: [15388457](#)
32. Schul W, Liu W, Xu HY, Flamand M, Vasudevan SG. A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. *J Infect Dis*. 2007; 195(5):665–74. PMID: [17262707](#)
33. Eyer L, Valdés JJ, Gil V a., Nencka R, Hřebabecký H, Šála M, et al. Nucleoside Inhibitors of Tick-Borne Encephalitis Virus. *Antimicrob Agents Chemother*. 2015; 59(9):5483–93. doi: [10.1128/AAC.00807-15](#) PMID: [26124166](#)
34. Rathore AP, Paradkar PN, Watanabe S, Tan KH, Sung C, Connolly JE, et al. Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse model. *Antiviral Res*. 2011; 92:453–60. doi: [10.1016/j.antiviral.2011.10.002](#) PMID: [22020302](#)
35. Sarathy VV, White M, Li L, Gorder SR, Pyles RB, Campbell GA, et al. A lethal murine infection model for dengue virus 3 in AG129 mice deficient in type I and II interferon receptors leads to systemic disease. *J Virol*. 2015; 89:1254–66. doi: [10.1128/JVI.01320-14](#) PMID: [25392217](#)
36. Foy BD, Kobylinski KC, Chilson Foy JL, Blitvich BJ, Travassos da Rosa A, Haddock AD, et al. Probable non-vector-borne transmission of Zika virus, Colorado, USA. *Emerg Infect Dis*. 2011; 17:880–2. doi: [10.3201/eid1705.101939](#) PMID: [21529401](#)
37. Musso D, Roche C, Robin E, Nhan T, Teissier A, Cao-Lormeau VM. Potential sexual transmission of Zika virus. *Emerg Infect Dis*. 2015; 21(2):359–61. doi: [10.3201/eid2102.141363](#) PMID: [25625872](#)
38. Petrilli V, Papin S, Tschopp J. The inflammasome. *Curr Biol*. 2005; 15(15):R581. doi: [10.1016/j.cub.2005.07.049](#) PMID: [16085473](#)
39. Tappe D, Pérez-Girón JV, Zammarchi L, Rissland J, Ferreira DF, Jaenisch T, et al. Cytokine kinetics of Zika virus-infected patients from acute to convalescent phase. *Med Microbiol Immunol*. 2015 Dec 24. [Epub ahead of print]
40. Sarathy VV, Milligan GN, Bourne N, Barrett AD. Mouse models of dengue virus infection for vaccine testing. *Vaccine*. 2015; 33(50):7051–60. doi: [10.1016/j.vaccine.2015.09.112](#) PMID: [26478201](#)